Grifols (NASDAQ:GRFS) Shares Down 2.7% – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares dropped 2.7% during mid-day trading on Friday . The stock traded as low as $7.48 and last traded at $7.51. Approximately 203,161 shares were traded during trading, a decline of 89% from the average daily volume of 1,823,070 shares. The stock had previously closed at $7.72.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Stock Performance

The firm has a market capitalization of $5.19 billion, a price-to-earnings ratio of 7.78 and a beta of 0.43. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The stock’s fifty day moving average is $8.37 and its two-hundred day moving average is $8.10.

Institutional Trading of Grifols

Hedge funds have recently made changes to their positions in the business. Hantz Financial Services Inc. acquired a new stake in Grifols during the 2nd quarter valued at $1,235,000. Natixis Advisors LLC lifted its stake in shares of Grifols by 116.0% during the 2nd quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock worth $971,000 after buying an additional 82,723 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Grifols by 56.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 55,887 shares of the biotechnology company’s stock worth $352,000 after buying an additional 20,120 shares during the period. Black Creek Investment Management Inc. grew its position in shares of Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after purchasing an additional 881,155 shares during the last quarter. Finally, Highland Peak Capital LLC acquired a new stake in Grifols during the 2nd quarter worth approximately $5,991,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.